These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35255965)

  • 1. Six-month outcomes of the HOPE smartphone application designed to support treatment with medications for opioid use disorder and piloted during an early statewide COVID-19 lockdown.
    Hodges J; Waselewski M; Harrington W; Franklin T; Schorling K; Huynh J; Tabackman A; Otero K; Ingersoll K; Tiouririne NA; Flickinger T; Dillingham R
    Addict Sci Clin Pract; 2022 Mar; 17(1):16. PubMed ID: 35255965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.
    Schramm ZA; Leroux BG; Radick AC; Ventura AS; Klein JW; Samet JH; Saxon AJ; Kim TW; Tsui JI
    Addict Sci Clin Pract; 2020 Jul; 15(1):30. PubMed ID: 32736660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Mobile Health App to Support Patients Receiving Medication-Assisted Treatment for Opioid Use Disorder: Development and Feasibility Study.
    Waselewski ME; Flickinger TE; Canan C; Harrington W; Franklin T; Otero KN; Huynh J; Waldman ALD; Hilgart M; Ingersoll K; Ait-Daoud Tiouririne N; Dillingham RA
    JMIR Form Res; 2021 Feb; 5(2):e24561. PubMed ID: 33620324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MySafeRx: a mobile technology platform integrating motivational coaching, adherence monitoring, and electronic pill dispensing for enhancing buprenorphine/naloxone adherence during opioid use disorder treatment: a pilot study.
    Schuman-Olivier Z; Borodovsky JT; Steinkamp J; Munir Q; Butler K; Greene MA; Goldblatt J; Xie HY; Marsch LA
    Addict Sci Clin Pract; 2018 Sep; 13(1):21. PubMed ID: 30249279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a pharmacist-led substance use disorder transitions of care clinic on postdischarge medication treatment retention.
    Smith A; Hansen J; Colvard M
    J Subst Abuse Treat; 2021 Nov; 130():108440. PubMed ID: 34118708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
    Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
    JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Smartphone intervention to optimize medication-assisted treatment outcomes for opioid use disorder: study protocol for a randomized controlled trial.
    Thompson RG; Bollinger M; Mancino MJ; Hasin D; Han X; Bush KA; Kilts CD; James GA
    Trials; 2023 Apr; 24(1):255. PubMed ID: 37016394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine.
    Hui D; Weinstein ZM; Cheng DM; Quinn E; Kim H; Labelle C; Samet JH
    J Subst Abuse Treat; 2017 Aug; 79():12-19. PubMed ID: 28673522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 Adaptations in the Care of Patients with Opioid Use Disorder: a Survey of California Primary Care Clinics.
    Caton L; Cheng H; Garneau HC; Fisher T; Harris-Mills B; Hurley B; Newman S; McGovern MP
    J Gen Intern Med; 2021 Apr; 36(4):998-1005. PubMed ID: 33511572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.
    Frost MC; Lampert H; Tsui JI; Iles-Shih MD; Williams EC
    Addict Sci Clin Pract; 2021 Oct; 16(1):62. PubMed ID: 34635170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the impact of social distancing measures implemented during COVID-19 pandemic on medications for opioid use disorder in West Virginia.
    Haggerty T; Khodaverdi M; Dekeseredy P; Wood N; Hendricks B; Peklinsky J; Sedney CL
    J Subst Abuse Treat; 2022 May; 136():108687. PubMed ID: 34903397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world evidence for a prescription digital therapeutic to treat opioid use disorder.
    Maricich YA; Xiong X; Gerwien R; Kuo A; Velez F; Imbert B; Boyer K; Luderer HF; Braun S; Williams K
    Curr Med Res Opin; 2021 Feb; 37(2):175-183. PubMed ID: 33140981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient Barriers and Facilitators to Medications for Opioid Use Disorder in Primary Care.
    Tofighi B; Williams AR; Chemi C; Suhail-Sindhu S; Dickson V; Lee JD
    Subst Use Misuse; 2019; 54(14):2409-2419. PubMed ID: 31429351
    [No Abstract]   [Full Text] [Related]  

  • 14. Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine.
    Du CX; Shi J; Tetrault JM; Madden LM; Barry DT
    Fam Pract; 2022 Mar; 39(2):234-240. PubMed ID: 34893825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Patient-Oriented App (ThessHF) to Improve Self-Care Quality in Heart Failure: From Evidence-Based Design to Pilot Study.
    Bakogiannis C; Tsarouchas A; Mouselimis D; Lazaridis C; Theofillogianakos EK; Billis A; Tzikas S; Fragakis N; Bamidis PD; Papadopoulos CE; Vassilikos VP
    JMIR Mhealth Uhealth; 2021 Apr; 9(4):e24271. PubMed ID: 33847599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study.
    Carter J; Li Z; Chen H; Greiner M; Bush C; Bhattacharya D; Poley S; Sachdeva N; Crowder JC; Feigal J
    Addict Sci Clin Pract; 2022 Nov; 17(1):60. PubMed ID: 36335381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient navigation for pregnant individuals with opioid use disorder: Results of a randomized multi-site pilot trial.
    Cochran G; Smid MC; Krans EE; Yu Z; Carlston K; White A; Abdulla W; Baylis J; Charron E; Okifugi A; Gordon AJ; Lundahl B; Silipigni J; Seliski N; Haaland B; Tarter R
    Addiction; 2024 Mar; 119(3):544-556. PubMed ID: 37859587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. General Behavioral Engagement and Changes in Clinical and Cognitive Outcomes of Patients with Type 2 Diabetes Using the Time2Focus Mobile App for Diabetes Education: Pilot Evaluation.
    Batch BC; Spratt SE; Blalock DV; Benditz C; Weiss A; Dolor RJ; Cho AH
    J Med Internet Res; 2021 Jan; 23(1):e17537. PubMed ID: 33470947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prior National Drug Abuse Treatment Clinical Trials Network (CTN) opioid use disorder trials as background and rationale for NIDA CTN-0100 "optimizing retention, duration and discontinuation strategies for opioid use disorder pharmacotherapy (RDD)".
    Shulman M; Weiss R; Rotrosen J; Novo P; Costello E; Nunes EV
    Addict Sci Clin Pract; 2021 Mar; 16(1):15. PubMed ID: 33676577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
    Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
    Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.